Trial Profile

A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotatercept (Primary) ; Melphalan; Prednisolone; Thalidomide
Indications Cancer metastases; Multiple myeloma
Focus Adverse reactions; Biomarker; Therapeutic Use
Sponsors Celgene Corporation

Most Recent Events

12 Mar 2010 Celgene Corporation added as trial sponsor as reported by ClinicalTrials.gov.
11 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
11 Mar 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com